# Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

> **NCT02370095** · PHASE2 · TERMINATED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 14 (actual)

## Conditions studied

- Respiratory Distress Syndrome, Adult

## Interventions

- **DRUG:** Treprostinil Inhalation Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02370095
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2017-10-11
- **Final completion:** 2017-11-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370095, "Treprostinil Sodium Inhalation for Patients At High Risk for ARDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02370095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*